Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 5/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.39 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PPID | Q08752 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10887590 | 1.00 | SLC7A5 (0.52) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP | |
| Hydrochloric Acid SCHEMBL818970 | 1.00 | SLC7A5 (0.52) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP | |
| SCHEMBL133092 | 0.98 | SLC7A5 (0.54) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP | |
| SCHEMBL196637 | 0.98 | SLC7A5 (0.54) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP | |
| SCHEMBL839402 | 0.98 | SLC7A5 (0.54) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP | |
| Hydrochloric Acid SCHEMBL6846663 | 0.94 | SLC7A5 (0.50) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP | |
| SCHEMBL10866196 | 0.92 | SLC7A5 (0.48) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP | |
| Phosphoric Acid SCHEMBL28734810 | 0.90 | SLC7A5 (0.47) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP | |
| Sulfuric Acid SCHEMBL28734782 | 0.90 | SLC7A5 (0.47) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP | |
| SCHEMBL28856635 | 0.88 | SLC7A5 (0.45) | SLC7A5ALOX15SLC1A3SLC1A2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12623994-B2 | Method of preparing heterogeneous linear carbonate using catalyst having excellent solubility | LOTTE CHEMICAL CORPORATION (KR) | 2026-05-12 | — | — | US | claimed |
| CN-117897386-A | Benzopyran derivatives and uses thereof | 斯帕克生物制药有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-11925644-B2 | Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and l-leucine ethyl ester | MERCK PATENT GMBH (DE) | 2024-03-12 | — | — | US | claimed |
| US-20240002329-A1 | METHOD OF PREPARING HETEROGENEOUS LINEAR CARBONATE USING CATALYST HAVING EXCELLENT SOLUBILITY | LOTTE CHEMICAL CORPORATION (KR) | 2024-01-04 | — | — | US | claimed |
| EP-4253363-A1 | METHOD FOR PRODUCING HETEROGENEOUS LINEAR CARBONATES USING CATALYST WITH EXCELLENT SOLUBILITY | Lotte Chemical Corporation (KR) | 2023-10-04 | — | — | EP | claimed |
| EP-3817813-B1 | CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-LEUCINE ETHYL ESTER | MERCK PATENT GMBH (DE) | 2023-09-20 | — | — | EP | claimed |
| CN-116710426-A | Method for preparing heterogeneous linear carbonate by using catalyst with excellent solubility | 乐天化学株式会社 | 2023-09-05 | — | — | CN | claimed |
| WO-2023277656-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | (주)스파크바이오파마 | 2023-01-05 | — | — | WO | claimed |
| CN-114456108-A | N-amino acid ethyl ester nicotinamide and preparation method and application thereof | 珀莱雅化妆品股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| US-20210283136-A1 | CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-LEUCINE ETHYL ESTER | MERCK PATENT GMBH (DE) | 2021-09-16 | — | — | US | claimed |
| CN-112979485-A | Application of 3A type molecular sieve in synthesis of N- (4-acetylene benzene carbonyl) amino acid ester | 齐鲁工业大学 | 2021-06-18 | — | — | CN | claimed |
| EP-3817813-A1 | CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-LEUCINE ETHYL ESTER | Merck Patent GmbH (DE) | 2021-05-12 | — | — | EP | claimed |
| CN-112312968-A | Crystalline salts of 5-methyl- (6S) -tetrahydrofolic acid and ethyl L-leucine | 默克专利股份有限公司 | 2021-02-02 | — | — | CN | claimed |
| WO-2020007839-A1 | CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-LEUCINE ETHYL ESTER | MERCK PATENT GMBH (DE) | 2020-01-09 | — | — | WO | claimed |
| EP-3082778-B1 | STABLE LIQUID FILLED HARD CAPSULE COMPRISING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID | CAPSUGEL BELGIUM NV (BE) | 2019-04-03 | — | — | EP | claimed |
| US-20160296475-A1 | STABLE LIQUID FILLED HARD CAPSULE COMPRISING BETA-HYDROXY-BETA METHYLBUTYRIC ACID | CAPSUGEL BELGIUM NV (BE) | 2016-10-13 | — | — | US | claimed |
| CN-102388017-A | A method of synthesising an amino acid derivative of azelaic acid | MALAYSIAN PALM OIL BOARD | 2012-03-21 | — | — | CN | claimed |
| WO-2010117258-A1 | A METHOD OF SYNTHESISING AN AMINO ACID DERIVATIVE OF AZELAIC ACID | MALAYSIAN PALM OIL BOARD (MY) | 2010-10-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12623994-B2 | Method of preparing heterogeneous linear carbonate using catalyst having excellent solubility | MLEC, MSMO1, ADH1C | GAA 1849/4885SLC7A5 1046/4885ALOX15 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.